Article: Connecting Institutions and Global Sites: Q&A With Sofia Baig, President of Clinical Solutions at Precision for Medicine
As clinical trial protocols have become more complex in recent years, institutions are facing new challenges in keeping up with the advancements. In this Q&A, Precision’s Sofia Baig, President of Clinical Solutions, discusses the challenges these institutions are facing, how sites can keep pace with new technologies, and improving efficiency in early and later phase research.
Article: Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy?
The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside. Precision’s Deb Phippard surveys the landscape in MedCity News.
Article: Bringing psychedelic medicine from the margins to the mainstream
Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.
Article: AAV-based gene therapies hold promise for treating CNS conditions
Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations. AAV-based therapeutics have been the most successful in vivo gene therapies for patients with central nervous system disorders. Precision’s Deb Phippard identifies challenges to their development with assessing, minimizing and mitigating immunogenicity.
Article: Breaking barriers: strategies for expanding patient access to cell and gene therapies
Despite a potentially record-breaking year for the cell and gene therapy industry, certain challenges remain. Precision’s Anshul Mangal identifies ways innovation can overcome hurdles that may ultimately stand in the way of broader accessibility.